Skip to main content

ORACEA Capsules Provide Multiple Benefits Over Doxycycline 100 mg2,3 ORACEA Capsules Doxycycline 100 mg

Superior GI tolerability compared to 100 mg2

In a head-to-head clinical study, no nausea, diarrhea or vomiting were reported for ORACEA Capsules (vs 17.3%, 4.3% and 4.3% for doxycycline 100 mg)

 Yes No

No evidence of bacterial resistance in a 9-month study3

ORACEA Capsules are precisely formulated (30 mg immediate release/10 mg delayed release) to treat the inflammatory lesions associated with rosacea without increasing the risk of antibiotic resistance.

 Yes No

No photosensitivity or vaginal candidiasis reported in controlled clinical studies3

 Yes No

In pivotal clinical studies, the most common treatment-related adverse events (>2%) for ORACEA Capsules were nasopharyngitis (4.8%), diarrhea (4.5%), hypertension (3%), sinusitis (2.6%), and aspartate aminotransferase increase (2.2%).

Help your patients see a positive difference

Not actual patients. Individual results may vary. Results are simulated to show average improvement in clinical trials.

IGA (Investigator’s Global Assessment) Scale

  • 4 - Severe

    Numerous small and/or large papules/pustules, severe erythema

  • 3 - Moderate

    Several small or large papules/pustules, moderate erythema

  • 2 - Mild

    Few small papules/pustules, mild

  • 1 - Almost Clear

    Very few small papules/pustules, very mild erythema present

  • 0 - Clear

    No inflammatory lesions present, no erythema